CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 22 enrolled
Drug / intervention
Biotin labeldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04476277
NCT04476277Early Ph 1Completed

Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease

National Heart, Lung, and Blood Institute (NHLBI)·interventional·Posted Jul 20, 2020·Updated Feb 13, 2024

In Brief

A Early Phase 1 clinical trial evaluating Biotin label for Sickle Cell Disease and Sickle Cell Anemia. Completed, enrolled 22 participants across 1 site.

Detailed Summary

Background: Sickle cell disease (SCD) is an inherited blood disorder. It results from a single genetic change (mutation) in red blood cells (RBCs). RBCs are the cells that carry oxygen to the body. In people with SCD, some RBCs are abnormal and die early. This leaves a shortage of healthy RBCs. Researchers want to learn more about how long RBCs live in the human body. Objective: To study how long RBCs live in people with and without SCD. Eligibility: People age 18 and older who either have SCD, had SCD but were cured with a bone marrow transplant, have the sickle cell trait (SCT), or are a healthy volunteer without SCD or SCT Design: Participants will be screened with a medical history and physical exam. They will give a blood sample. Participants will have a small amount of blood drawn from a vein. In the laboratory, the blood will be mixed with a vitamin called biotin. Biotin sticks to the outside of RBCs without changing their function, shape, or overall lifetime. This process is known as biotin labeling of RBCs. The biotin labeled RBCs will be returned to the participant via vein injection. Participants will give frequent blood samples. Their RBCs will be studied to see how many biotin labeled RBCs remain over time. This shows how long the RBCs live. Participants will give blood samples until no biotin labeled RBCs can be detected. During the study visits, participants will report any major changes to their health. Participation lasts for up to 6 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
202120222023202420252026
First PostedJul 20, 2020
Enrollment StartApr 19, 2021
Primary CompletionDec 20, 2022
Study CompletionFeb 14, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.0 years ago

Interventions

Biotin labeldrug

Autologous cells will be collected and biotin-labeled ex vivo and reinfused to measure red cell survival